

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT® Code Change Applications

February 2023 Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its February 2023 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on December 2, 2022. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full May Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of the corresponding year.**

NOTICE –INTERESTED PARTY PROCESS

Upon review of this agenda, if the reviewer believes that they will need to provide comment on an issue, they must seek Interested Party status by [submitting a request](#) for a copy of the application and associated materials. **Only requests submitted through Zendesk will be approved.** This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

Updated November 14, 2022

- New
- ▲ Revision
- ✚ Add on
- ✖ Deletion

*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form. Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
Request for Code Change Application Materials	Nov. 21, 2022
Submission of Written Comments	Dec. 2, 2022

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the February 2023 meeting, which will be published on or before March 3, 2023 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Updated November 14, 2022

- New
- ▲ Revision
- ✚ Add on
- ✖ Deletion

Name	Code #	Request-Description
GSP-Tumor Genomics Testing	▲81445-▲81456 ● 8X017 ● 8X018 ● 8X019 ● 8X020 ● 8X021 ● 8X022	Revise codes 81445-81456 and to establish codes 8X017-8X022 to reflect current practice in genomic sequencing technology for somatic mutation and cancer treatment
App O Proprietary Name Revision-81490	81490	Revise the proprietary name and clinical laboratory or manufacturer in Appendix O for code 81490
MAAA-Enhanced Liver Fibrosis Assay	● 8X025	Establish MAAAs code 8X025 to report enhanced liver fibrosis disease testing
Anti-Mullerian Hormone (AMH)	● 8X016	Establish code 8X016 to report AMH (Anti-Mullerian Hormone) assay
Muscle-Specific Kinase (MuSK) Autoantibody	● 8X026	Establish Category I code 8X026 to identify testing for Muscle Specific Kinase (MuSK) antibodies
Sexually Transmitted Infection - New Panels	● 8X023 ● 8X024	Establish codes 8X023, 8X024 to report an amplified probe laboratory test for a sexually transmitted infection (STI) panel
Genetic Counseling Services	▲96040	Revise code 96040 and the guidelines to include total time during pre-, during and post- time in patient related activities on the date of encounter and preservice activities

Updated November 14, 2022

- New
- ▲ Revision
- ✚ Add on
- ✖ Deletion